Drug intelligence / Profile preview

LAE124

Development stage: Preclinical
Lead developer: Laekna

Overview

LAE124 is a preclinical drug candidate developed by Laekna for the treatment of obesity. It targets the amylin pathway, which is involved in the regulation of energy balance and glucose metabolism. Amylin is a hormone co-secreted with insulin that acts on the central nervous system to promote satiety and slow gastric emptying. By modulating this pathway, LAE124 aims to reduce appetite and body weight.

Targets

CALCR (Calcitonin receptor)AMY receptor (Calcitonin receptor (with ramps))

Beyond the preview

Go deeper on LAE124.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAE124.

Explore the full profile